Rheumatoid Arthritis Treatment Guidelines

Initial Treatment Approach

The European League Against Rheumatism recommends methotrexate (MTX) as the anchor drug and gold standard for RA treatment due to its established efficacy, acceptable safety profile, and low cost 1, 2, 3
Start with oral MTX at 15 mg/week, with dose escalation by 5 mg/month to a target of 25-30 mg/week (or highest tolerable dose) 1, 4
Folate supplementation is essential to reduce adverse effects and should be prescribed alongside MTX 3
MTX reaches maximum efficacy after 4-6 months of treatment, so maintain the optimal dose for at least 3 months before concluding efficacy 2, 5

For patients with inadequate response to oral MTX, switching to subcutaneous administration improves bioavailability, especially at doses >15 mg/week 4
The optimal evidence-based approach is starting with oral MTX 15 mg/week, escalating to 25-30 mg/week, then switching to subcutaneous administration if response is insufficient 4
In Asian populations, lower maximum doses (around 16 mg/week) may be appropriate due to lower body weight and potential pharmacogenetic differences 3

In cases of MTX contraindications (hepatic or renal disease) or early intolerance, leflunomide (20 mg/day) or sulfasalazine (3-4 g/day) should be considered as alternative first-line DMARDs 1, 5
Both leflunomide and sulfasalazine have shown efficacies similar to MTX in clinical trials 5
Sulfasalazine is considered safe during pregnancy, which may be an important consideration for women of childbearing potential 5

If MTX monotherapy fails to achieve low disease activity or remission after 6 months of optimal dosing, consider adding sulfasalazine and hydroxychloroquine to MTX (triple DMARD therapy) 6
Add a biologic agent such as TNF inhibitor (adalimumab, etanercept), abatacept, or tocilizumab 2, 6

Inadequate MTX dosing or premature switching to biologics before reaching optimal MTX dose and duration (at least 3-6 months) 2, 5
Failure to switch from oral to subcutaneous MTX before declaring MTX failure 4
Discontinuing MTX due to minor side effects that could be managed with folate supplementation or anti-emetics 3